Exploring Mechanisms of Action & Non-Canonical Approaches Against the RAS Pathway to Identify Promising Therapies
Time: 12:01 pm
day: Workshop B
Details:
The classic “undruggability” of RAS was overcome with the approval of Sotorasib, and now
again with the approval of Adagrasib. The push for new RAS inhibitors has been followed by the
emergence of many novel targeting approaches, such as degradation, protein modulation, and
nanoparticles. Hence, it is vital to bring together various experts to examine the RAS-targeting
landscape and tease out promising new modalities and targets.
This workshop will:
- Showcase various modalities to compile a list of our arsenal against mutant RAS
- Address the benefits and pitfalls of each approach to create a data-led landscape of the arsenal
- Benchmark the modalities to determine the most promising directions to target RAS
